ATRC vs. OFIX, ATEC, SRDX, IART, AORT, MDXG, EMBC, ATRI, SILK, and KIDS
Should you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Orthofix Medical (OFIX), Alphatec (ATEC), Surmodics (SRDX), Integra LifeSciences (IART), Artivion (AORT), MiMedx Group (MDXG), Embecta (EMBC), Atrion (ATRI), Silk Road Medical (SILK), and OrthoPediatrics (KIDS). These companies are all part of the "surgical & medical instruments" industry.
Orthofix Medical (NASDAQ:OFIX) and AtriCure (NASDAQ:ATRC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership.
Orthofix Medical presently has a consensus price target of $18.00, suggesting a potential upside of 20.00%. AtriCure has a consensus price target of $49.78, suggesting a potential upside of 115.12%. Given Orthofix Medical's stronger consensus rating and higher probable upside, analysts clearly believe AtriCure is more favorable than Orthofix Medical.
Orthofix Medical has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
AtriCure has a net margin of -8.98% compared to AtriCure's net margin of -16.64%. Orthofix Medical's return on equity of -7.85% beat AtriCure's return on equity.
In the previous week, AtriCure had 2 more articles in the media than Orthofix Medical. MarketBeat recorded 6 mentions for AtriCure and 4 mentions for Orthofix Medical. Orthofix Medical's average media sentiment score of 0.47 beat AtriCure's score of 0.34 indicating that AtriCure is being referred to more favorably in the news media.
AtriCure has lower revenue, but higher earnings than Orthofix Medical. AtriCure is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.
89.8% of Orthofix Medical shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 4.7% of Orthofix Medical shares are held by insiders. Comparatively, 3.2% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
AtriCure received 136 more outperform votes than Orthofix Medical when rated by MarketBeat users. Likewise, 68.98% of users gave AtriCure an outperform vote while only 61.80% of users gave Orthofix Medical an outperform vote.
Summary
AtriCure beats Orthofix Medical on 15 of the 18 factors compared between the two stocks.
Get AtriCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AtriCure Competitors List
Related Companies and Tools
